Alzheimer’s Drug From Biogen Wins US Approval
Service prices as we're seeing activity picking up Biogen has received approval for its controversial Alzheimer's disease, their appeal landmark decision that stands to dramatically change treatment for the debilitating brain condition. Bijan shares up now by 40.2%. Japan's A Sigh is working with Bijan on the Alzheimer's drug. It's a TRS are also surgeon today.